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Are Polypills a Viable Option to Improve Health Outcomes in Those
with Cardiovascular Disease?
Objective: Does the use of polypill therapy improve systolic blood pressure and low-density
lipoprotein cholesterol (LDL-C) levels more than usual care in adults with established
cardiovascular disease (CVD) or with 10-year atherosclerotic cardiovascular disease risk >10%.
Design: Systematic literature review. Methods: Searches were performed in PubMed and
UpToDate using the following search terms polypill and cardiovascular. Other limits included:
randomized control trials, adults, published in the last 10 years, LDL-C and systolic blood
pressure. Results: Analysis of articles to ensure similar design, intervention and fit with the
other inclusion/exclusion criteria yielded three studies: Labefer et al, Muñoz et al, and Patel et
al.9,10,11 Conclusion: The polypill should be considered in all adults who have a 10-year ASCVD
event risk >10% or those previously diagnosed with CVD. The polypill should particularly be
considered in subgroups such as those taking fewer than two anti-hypertensive medications,
patients who are failing to meet cholesterol goals with low potency statins or individuals that
face challenges accessing medications. Price and production of the polypill in the United States
remains to be seen and would have a significant impact on the clinical power of the polypill.

Introduction
Cardiovascular disease is the leading cause of death for men and women in the United
one in three deaths in the U.S each year is caused by heart disease or stroke. 2
The economic burden of cardiovascular disease was $219 billion dollars in 2014-2015, and its
impact disproportionately affects minority and ethnic groups.2,3
One of the lesser discussed risk factors for development of a cardiovascular disease is a
lack of medication compliance. The World Health Organization states adherence to medications
can have more of an impact on patient outcomes than the specific treatment itself.4 Among
patients with chronic illness, approximately 50% do not take medications as prescribed. 5 As
information from research provides new light about optimal dosing and drug to drug synergism,
the burden of medication navigation becomes increasingly more complex. In response to
increasing CVD prevalence and poor medication adherence, a fixed dose combination pill was
developed which includes an aspirin, a statin, and two anti-hypertensive medications.6
Compliance is further exacerbated in underserved areas where individuals have
inappropriate access to preventative medication and adherence is typically poor.7 African
Americans are 30% more likely to die from heart disease, twice as likely to have a stroke, 40%
more likely to have high blood pressure, and 10% less likely to have their blood pressure under
States.1 Nearly

control than their white counterparts. Mexican Americans have higher triglyceride levels, and
Puerto Ricans have the highest rate of death related to hypertension.7 Many minorities and
underserved regions experience far greater health disparities— especially related to
cardiovascular disease. Despite the potential benefits of the polypill, this pill is not yet available
to the American consumer.
A potential disadvantage of polypill therapy is the inability to tailor doses to the
individual, concomitantly, increasing the potential for adverse effects. Although studies have
been completed in several European nations, this review provides a meta-analysis of current
data to help evaluate the role and value the polypill could have in the United States.
A common guideline tool for stratifying patients is the Atherosclerotic Cardiovascular
Disease (ASCVD) calculator. This is a predication based on certain risk factors such as age, sex,
race, blood pressure, cholesterol levels, diabetes history, smoking history and if the individual is
currently taking anti-hypertensive medications. The calculation creates a 10-year risk of having
a cardiovascular related episode such as stroke or myocardial infarction and stratifies the risk
by levels: low <5%, borderline 5%-7.5%, intermediate 7.5%-20% and high >20%. This analysis
utilizes these stratifications to help with proper cross study patient comparison.
Clinical Question
In adults diagnosed with CVD or at a higher than borderline 10-year ASCVD risk who are
already prescribed a multiple drug regimen, does administration of a polypill (one statin, two
anti-hypertensive medications and an aspirin) show improved systolic blood pressure and LDL-C
compared to usual care after one year.

Methods
Search engines utilized included PubMed, Cochrane Library and Google. An initial search
was performed in September 2020 using MESH terms such as ‘polypill’ and ‘cardiovascular
disease’ which yielded 396 records. Records that were excluded were non-randomized control
trials, articles published before 2010, outcomes limited only to adverse events or did not
include cardiovascular outcomes, this yielded 36 results. Results that did not compare
intervention to usual care, included placebo control groups or did not trend LDL-C and blood
pressure were excluded. The three studies selected were individually assessed and validated by
comparing inclusion and exclusion criteria, funding and sample size. This process is depicted in
Figure 1: PRISMA Search Strategy and Table 1: Inclusion and Exclusion Criteria.

Figure 1: PRISMA Search Strategy

Table 1: Inclusion and Exclusion Criteria
Inclusion Criteria

Exclusion Criteria

Age > 18

Non-Randomized Control Trials

LDL-C and Systolic Blood Pressure measured
as an outcome

Outdated research > 10 years of age

Polypill therapy that focused on
cardiovascular disease treatment and risk
factors

Only adverse events recorded as primary
outcomes
Polypill formulations that did not contain
aspirin, two anti-hypertensive medications
and a statin

Results
Study #1
Impact of switching from different treatment regimens to a fixed-dose combination polypill in
patients with cardiovascular disease or similarly high risk.9
Objective: This study evaluated the impact of different polypill treatment regimens on
cardiovascular risk factors.
Study Design
This is a post-hoc analysis of the UMPIRE trial which was a randomized, open label,
blinded trail comparing a polypill-based treatment strategy against usual care in those with
established cardiovascular disease or those at similar level of high risk; defined as a 5 year
event risk > 15%. The study took place in India and three European countries England, Ireland,
Netherlands. In total, 2004 participants were included in the study. Patients were randomized
at a 1:1 ratio between the usual treatment group and polypill group. With 1002 of those
participants assigned to the polypill. Further, broken down into 589 of those assigned to version
one of the pill and 413 assigned to version 2 of the pill. The primary endpoint for the study
looked at adherence to medication regimens and whether LDL-C and systolic blood pressure
(BP) improved. The participants assigned to usual care continued to be seen by their routine
doctor. Those assigned to the polypill group were prescribed one of the two polypill versions, at
the discretion of the prescribing physician and as visualized in Table 2.
Table 2. Medications included in Polypill formulation
Version 1 Polypill

Aspirin 75 mg, Simvastatin 40 mg, Lisinopril
10 mg, Atenolol 50 mg

Version 2 Polypill

Aspirin 75 mg, Simvastatin 40 mg, Lisinopril
10 mg, Hydrochlorothiazide 12.5 mg

The end of study visit for all participants was scheduled to take place 12 months after
the random assignment of the last participant. Telephone and clinic visits were conducted at 1
month and 6 months. Fasting lipids and BP were measured at baseline and at previously the
stated visits.
The polypill medication potency was compared to those statin therapies that had LDL
reductions of 32% to 40% were defined as equally potent to the polypill (Fluvastatin 80 mg,
pravastatin 80 mg, simvastatin 40 mg, atorvastatin 10 mg and rosuvastatin 5 mg). The antihypertensive medications such as beta blockers, ACE-Inhibitors, angiotensin receptor blockers,
calcium channel blockers at standard doses have all shown similar reduction in BP. The

reduction of LDL-C and systolic BP was calculated as the difference from baseline at follow -up.
Data from 1, 6 month and 12 months were used in the analysis of BP and LDL-C for all
participants who were required to attend these visits. Criteria for Study 1 is depicted below in
Table 3.

Table 3 Study Population Criteria for Study 1
Inclusion Criteria

Exclusion criteria

Age > 18

Contraindications for medications

Cardiovascular disease dx or 5-year cardiac
risk > 15% according to ASCVD calculator

Doctor considered changing the medications
inappropriate

Had to have clear indications to take the
medications

Patient was unlikely to complete study
Medication may be altered for long period of
time

Study Results
Antiplatelet Therapy
Those in either polypill group saw an increase from baseline of 6% reported usage
compared to 3% reported usage increase for the non-polypill group. This showed a relative risk
of adherence of 1.08.
Antihypertensive medications
In those in the polypill group, there was a reduction mean BP of 5.4, 6.2, 3.3, 1.8 mmHg
in those patients taking 0, 1, 2, or 3 BP lowering agents prior to the study respectively.
Statin Therapy
Those in the polypill group saw a 11% increase in adherence, self-reported at every visit,
after randomization and there was a 7 % increase in adherence in the usual care group
compared to baseline resulting in a RR of 1.05. There was a .37, .22, .14 and .07 mmol/L mean
lowering difference from patients taking no statins, less potent, equipotent and more potent
statins at baseline.
Overall cardiovascular risk
The overall estimated mean cardiovascular risk reduction was 12.6% in the polypill
group than the usual care group, with a reduction of .15 LDL-C and 3.4 systolic BP points when
compared to the usual care group.
Study Critique

Those who participated in the clinical trial were more motivated and may have resulted
in a overestimation on the impact of the intervention compared to usual care. The individuals in
the study receiving the polypill did not have to pay for the medication due to European
regulations and this may have altered adherence; by as much as 5% as demonstrated by a large
trial in the United State done by Choudhry NK et al.13 The price of the polypill ranges from 0.2323.12 dollars a day, which is within the range of the sum of the components. Thus, there is not
a huge financial advantage to the polypill as relayed in this study.

Study #2
Polypill For Cardiovascular Disease Prevention in an Underserved Population.10
Objective: Evaluate if polypill-based therapy compared against usual care in economically
vulnerable populations in the US produces cardiovascular disease benefit.
Study Design
This was an open label, randomized control trial with 303 adults who lived within 50mile radius of the Franklin Primary Health Center in Mobile, Alabama. The average 10-year
cardiovascular risk of participants in this study is 12.7%. Table 4 includes inclusion and exclusion
criteria for study #2.
Table 4: Study Criteria for Study 2
Inclusion Criteria

Exclusion Criteria

Age: 45-75

Did not want to participate

Reported no history of coronary heart
disease, stroke, cancer, liver disease, or
insulin-dependent diabetes

Did not fill out questionnaire (as part of
eligibility and screening)

Systolic BP between 120mmHg and
160mmHg

Did not complete clinical exam (as part of
screening)

LDL-C level of less than 190 mg per deciliter

Did not meet inclusion criteria

An estimated glomerular filtration rate of at
least 60 ml per minute per 1.73 m2 of bodysurface area
Normal potassium levels and hepatic
aminotransferase levels of less than three
times the upper limit of the normal range
No contraindications to any polypill

component
Not pregnant
Current use of no more than two
antihypertensive medications
*This upper limit was later removed following approval from the institutional review board and
the data and safety monitoring board.
Of the 303 participants enrolled, 148 were allocated to polypill therapy and 155
participants were allocated to usual care. Over a 12-month period changes in systolic blood
pressure, LDL-C and other cholesterol levels were measured and compared to baseline.
Following randomization, all participants from both arms were scheduled for follow-up visits at
2 and 12 months. During the trial visits a clinical examination was conducted, blood pressure
measured by a trial nurse utilizing appropriately sized cuff, and a fasting blood sample collected
by a trained phlebotomist.
The polypill group received 90-day refillable supplies of daily trial medication. The
polypill was a gelatin capsule containing four generic drug components: atorvastatin (10 mg),
amlodipine (2.5mg), losartan (25mg), and hydrochlorothiazide (12.5mg). The initial polypill was
shipped overnight to the participants residence and subsequent refills were filled at the
Franklin Primary Health Center.
Blood-pressure data was calculated by the mean of two resting, manual, in-clinic
measurements. The Martin-Hopkins equation was utilized to calculate the LDL-C level. At trial
visits a trial coordinator performed pill counts to assess compliance to the polypill regimen.
Study Results
Adherence to the polypill regime was 86% based on unused pills counted at trial visits.
In the polypill arm, 44% of participants had previous antihypertensives or lipid lowering
medication reduced or discontinued by clinicians, with an escalation of therapy in 2% of
patients. The usual care arm had no discontinuation or de-escalation of medication by
clinicians, with a 10% escalation of therapy in participants.
The polypill group had a mean systolic decrease in blood pressure by 9mmHg, whereas
the usual-care groups had a mean 2 mmHg decrease in blood pressure. (95% CI, P=.003) The
mean LDL-C decreased in the polypill arm by 15mg per deciliter whereas the usual care arm had
a mean decreased of 4 mg per deciliter. (95% CI, P<.001)
Study Critique
High compliance was a strength of the study- as 91% of the participants completed 12
months of the trial. There are few distinct aspects of this trail as 96% of the participants were
black, thus these results may not be as applicable to white counterparts as patterns of
cardiovascular disease risk factors may vary across different races. Second, the trial was
conducted at a single federally qualified community health center and thus may be difficult to
apply to differing settings.

The polypill group was not charged for the medication and thus introduced the
possibility that lower costs impacted the results. Lastly, a large limit to this study was the openlabel design. Although created for clinician flexibility to adjust medications, this likely altered
the medication escalation and or de-escalation results.

Study #3
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive
treatments in people at high cardiovascular disease risk.11
Objectives: This study aimed to determine whether fixed dose combinations of generic drugs
would promote the use of cardiovascular disease risk reducing medications.
Study Design
The study was an open label randomized trial of 623 participants in general practices
throughout Australia. Participants included had either an established CVD risk, an estimated 5year ASCVD event risk >15% or has indications for combination therapy consisting of
antiplatelet medication, statin and greater than or equal too anti-hypertensive medications.
The study also included a 5% increment on the Framingham risk equation for those who
identified as Aboriginals or Torres Strait Islander. The two versions of the polypill used and their
formulations can be found in Table 5. Inclusion and exclusion criteria can be found in Table 6.
Computer based randomization to polypill strategy or usual care was completed and
further stratified by primary healthcare center, type of indication, indigenous identification and
level of preventative treatment at baseline. All patients were treated by their regular doctor
regardless of group and no attempt was made to alter the treatment of the usual care patients.
Those in the polypill group received the medication as instructed by the provider. In
either group, the provider could alter the polypill medication treatment with adding additional
medications or withdraw the polypill. Out of pocket expenses for the polypill were identical to
those any other drugs listed in the Pharmaceutical Benefits Scheme.
Participants had scheduled BP and cholesterol level checks at baseline, 12 months, 24
months and at the final visit. Self-reported use of all medications was reviewed at all visits.
Primary endpoints included changes in systolic BP and total cholesterol from baseline.
Secondary endpoints included renal events, serious adverse cardiovascular events among
others.
Table 5. Medications included in study polypill formulation
Version 1 Polypill

Aspirin 75 mg, Simvastatin 40 mg, Lisinopril
10 mg, Atenolol 50 mg

Version 2 Polypill

Aspirin 75 mg, Simvastatin 40 mg, Lisinopril
10 mg, Hydrochlorothiazide 12.5 mg

Table 6. Study Criteria for Study 3
Inclusion Criteria

Exclusion Criteria

Age > 18

Contraindications for to any component of
polypill

Established CVD (peripheral vascular,
cerebrovascular or coronary ischemia)

Patient felt like it was clinically inappropriate
to alter medications

5-year CVD risk greater than or equal to 15%

Study Results
Primary measurement outcomes included medication use, systolic BP, and total
cholesterol. 70.1% of participants in the polypill group reported compliance to medication
regimen, 46.9% of participants in the usual care group reported compliance to their medication
regime. (RR 1.49, CI 1.30- 1.72, p<.0001).
Mean baseline systolic BP for polypill arm was 143.4 mmHg and at end of study (30
months) the mean systolic BP was 139 mmHg. Mean baseline systolic BP for usual care was
142.5 mmHg, and the end of study results had a mean systolic BP of 140.3 mmHg.
Total mean cholesterol in the polypill group at baseline was 4.4mmol/l and at end of
study was 4.39 mmol/l. Total mean cholesterol at baseline was 4.5mmol/l and at the end of the
study was 4.31mmol/l.
Secondary endpoint of LDL-C levels showed no difference at the end of the study when
comparing the usual care arm to the polypill treatment groups (p=.36).
Study Critique
Although a prominent finding was the difference in compliance in the polypill arms vs
usual care, these measurements were self-reported and may not truly reflect compliance. Pill
counts may have been a stronger measure. This study did not recruit as many participants as
originally estimated due to resource limitations and is considered underpowered. This trial had
an open label design and thus introduced the possibility that over-reporting could have
differentiated in medication use.

Discussion
Cardiovascular disease is very common medical condition and can frequently result in
fatal outcomes that could be prevented. When lifestyle modifications are not enough to
prevent adverse complications of CVD, a multi-mediation regime becomes commonplace.
Although there is benefit in tailoring a therapy to the individual within a multi-medication

regimen, it can be cumbersome. Especially for those facing disadvantages such as those who
are economically challenged, living in rural areas, or identified as a minority, these factors
independently or in combination can be barriers in adherence to multiple drug therapy. The
purpose of this review is to determine if polypill-based therapy, a fixed dose combination of
generic drugs in a single pill, compared against usual care would produce a cardiovascular
disease benefit— with emphasis on application in underserved populations.
An overview of the studies is included in Table 7. Lafeber et al and Patel et al are similar
to one another in that CVD inclusion criteria more closely mirrored each other such as sharing
exactly similar polypill therapy and used similar interpretation measures.9,11 More noteworthy
was the interpretation measures used in Muñoz et al via manual BP taken by a nurse and pill
counts to assess adherence rather than automated BP readings and self-reporting in the other
two studies.10
All three studies were similar in that they were an open label design and shared similar
age and gender demographics. All three studies differed in their length of trial, patient number
and population.
Lafeber et al assessed a more diverse population, both through differing location and
medical settings.9 Whereas Muñoz et al assessed a largely all black population in a single rural
setting. Patel et al assessed many locations (33 centers) in similar settings, all general practice
settings in Australia.10,11
Table 7: Overview of Studies
Lafeber et al

Muñoz et al

Patel et al

Patients, N

2004

303

623

Population

Adults living in
England, Ireland,
Netherlands and
India recruited via
clinics, hospitals,
general practice and
databases

Adults living within
50-mile radius of the
Franklin Primary
Health Center in
Mobile, Alabama.
96% of participants
are African American.

Adults in Australian
general practice
including a 5%
increment for
Aboriginal or Torres
Strait Islander
Identified

Gender/Age range

18% Women and 82% 60% woman 40%
Men, > 18 years
men, age 45-75

Average age of
participants

61.85 years

Women and Men, >
18 years

56 years

63.55 years

CVD risk

Established CVD or
those with high 5
year event risk > 15%

Average 10-year
cardiovascular risk of
participants is 12.7%

Established CVD or an
estimated 5-year CVD
risk >15%

Blinded

open label

open label

open label

Intervention (polypill
contents)

Version 1: Aspirin 75
mg, Simvastatin 40
mg, Lisinopril 10 mg,
Atenolol 50 mg.

Atorvastatin 10 mg,
Amlodipine 2.5mg,
Losartan 25mg, and
hydrochlorothiazide
12.5mg.

Version 2: Aspirin 75
mg, Simvastatin 40
mg, Lisinopril 10 mg,
Hydrochlorothiazide
12.5 mg.

Version 1: Aspirin 75
mg, Simvastatin 40
mg, Lisinopril 10 mg,
Atenolol 50 mg.
Version 2: Aspirin 75
mg, Simvastatin 40
mg, Lisinopril 10 mg,
Hydrochlorothiazide
12.5 mg.

Length of trial

24 months

12 months

30 months

Primary Interest

Adherence to
polypill, systolic BP,
and LDL-C compared
to usual care

Adherence to polypill
and
mean systolic B/P,
and LDL-C compared
to usual care

Adherence to
polypill, systolic B/P,
and total cholesterol
compared to usual
care

Adherence to
medication
interpretation

Self-reported at visit

Trial Coordinator
Self-reported at visit
performed pill counts
at visit

Blood pressure
interpretation

Electronic
oscillometric BP
monitor: Omron
705CP II

Manual B/P by Trial
Nurse

Electronic
oscillometric BP
monitor: Omron
705CP II

Table 8: Overview of Results
Lafeber et al

Muñoz et al

Patel et al

Overall adherence
change in polypill
arm

11% (using statin
adherence values)

N/A

25.2%

Overall adherence
change in usual care
arm

7% (using statin
adherence values)

N/A

-2.2%

Comparison

4%

N/A

27.4%

Significant?

Yes CI (1.04 to 1.07)

N/A

Yes CI (1.30-1.72)

Systolic BP changepolypill

-7.50 mmHg

-9mmHg

-4.4 mmHg

Systolic BP changenormal treatment

-4.12 mmHg

-2mmHg

-2.5 mmHg

Comparison

-3.38 mmHg

-7 mmHg

-1.9 mmHg

Significant?

Yes CI (-4.8--1.9)

Yes CI (-11--2) p=.002 No

Calculated LDL-C
change-polypill

-.2 mmol/L

-.40 mmol/l

-0.07 mmol/l

Calculated LDL-C
change normal
treatment

-.01 mmol/L

-.10mmol/l

-.16 mmol/l

Comparison

-.19 mmol/dl

-.30mmol/l

.09 mmol/l

Significant?

Yes CI (-.21 to -.09)

Yes CI (-.30--.45,
p<.001)

No

In those studies that included results analyzing adherence, the polypill treatment
groups had a significant improvement. Two of three studies-Lafeber et al and Muñoz et al
showed significant differences in BP levels. 9,10,11 Patel et al showed a BP decrease that was not
considered clinically significant. The largest decrease in BP of 7 mmHg was seen in the Muñoz
et al study. Both Lafeber et al and Muñoz et al saw decreases in LDL-C levels in the polypill arm
as compared to usual care.9,10 Conversely, Patel et al actually reported an increase in LDL-C
compared to the usual care arm.11 Which is a concerning finding as this study also reported
adherence to combination therapy. Results can also be found in Table 8: Overview of Results.
APPLICATION IN CLINICAL SETTINGS
All three studies reported higher adherence in the polypill group as compared to the
usual care group as the conclusion of the study. In regards to BP levels, two out of three studies
reported a statistically significant decrease in the polypill arm as compared to usual care. With
the largest decrease of 7mmHg in BP seen in the Muñoz et al study and thus could be
considered clinically significant. Both Lafeber et al and Muñoz et al saw decreases in LDL-C
levels in the polypill group as compared to usual care arm.9,10 However, Patel et al reported an
increase in LDL-C compared to usual care.11
The populations utilized in the studies are an important factor. Study two, Muñoz et al
was conducted in a population in rural Alabama— highlighting the potential to be extended to

similar populations within the U.S. However, price is a component that none of these studies
evaluated but is an important factor in adherence.10
Lastly, because the polypill contained preset medications, typically moderate statin
intensity and two anti-hypertensive medications, it did not show improvement in SBP or LDL-C
levels in individuals that were previously taking a more intense medication regime than what
was in the polypill. Thus, a drawback to polypill therapy is its lack in ability to individualize care
and would likely be less effective in more severe disease states which require high intensity
statins or 2 or more anti-hypertensive medications.

Conclusion
In adults 18-65 with diagnosed CVD or higher than borderline ASCVD risk who are taking a multimedication regimen, does administration of a polypill which includes a statin, 2 anti-hypertensive
medications and aspirin opposed to usual medication regime improve blood pressure and LDL-C levels.

Polypill therapy improved LDL-C levels and BP in two out of three studies. As polypill
therapy becomes available in the US, it could be considered as an alternative in patients taking
a multiple medication regime particularly those who are on one or two anti-hypertensive
medications, using a low potency statin and are also struggling with compliance or access to
medication. There are many questions to be resolved; what the potential price of this
pharmacological therapy would be, what concentrations of the components are best for
differing subgroups, but at this time it appears further studies are warranted to confirm the
most notable positive health findings as seen in Muñoz et al and Lafeber et al studies and
whether similar results would occur in different populations.10,9
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